Keratoderma, Palmoplantar Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Keratoderma, Palmoplantar. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Keratoderma, Palmoplantar receives a directional strategic score of 61/100. The synthesis combines unmet need (74/100), competitive intensity (78/100, where a higher value means more competition) and market attractiveness (75/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Group of mostly hereditary disorders characterized by thickening of the palms and soles as a result of excessive keratin formation leading to hypertrophy of the stratum corneum (hyperkeratosis).

The reproducible entity is Patsnap disease ID 2d0bc85a2661464bacd8500ea3ab5539 with MeSH identifier D007645. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Keratoderma, Palmoplantar, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database

DISCUSSION The current literature is extremely limited in its epidemiologic analysis of oMMP, with case studies comprising the bulk of the publications due to the rarity of the condition. Larger studies, mainly based out of Europe, have indicated varying incidence rates of 1 in 12,000 to 1 in 60,000 with no reports on prevalence [20, 21]. One study focused on the incidence and prevalence of oMMP in Colombia utilising the national health registry, and reported an average incidence of 0.24 per 1,000,000 individuals and an average prevalence of 0.22 per 1,000,000 [22]. The use of TriNetX limited to the population in the US allows for a culturally diverse group for analysis, despite the rarity of the condition, and a larger sample size for a more robust assessment of the incidence and prevalence results. Our study found an increasing incidence and prevalence across the 11-year period, which could not only be attributed to rising cases of the disease but also increased awareness of its presentation, stronger data collection, and overall better diagnosis. The treatment of oMMP is focused on halting the progression of fibrosis and controlling inflammation [3]. Systemic immuno­ suppressive drug therapy is the gold standard as topical treatment alone is insufficient and ineffective [23]. The choice of therapy often depends on the disease stage and severity. Most patients present with moderate to advanced disease, requiring aggressive treatment with biologics (such as rituximab) or 3260

Review the underlying epidemiology source

Epidemiology signal 2: Epidemiology of Autoimmune Liver Disease

) 유병률 원발경화담관염의 유병률에 관한 변동 측정(신뢰구간, 표 준편차 등) 보고가 불량하여 여러 연구를 취합한 자료는 없다. 가장 유병률이 높은 지역은 핀란드로서 2015년 ICD-10 코드 를 이용한 진료자료를 기반으로 10만 명당 31.7으로 보고하 였다.14 2005년 스웨덴 및 1995년 노르웨이 연구에서 유병률 은 각각 10만 명당 16.2, 8.5였다. 한편, 2005년 미국 캘리포 니아에서는 연령 보정 유병률이 10만 명당 4.03였고, 미네소 타에서는 13.6, 뉴질랜드에서는 13.2였다.13 2007년 설문조사 에 근거한 일본 연구에서 유병률은 10만 명당 0.95로 서구에 비해 낮았다.15 원발경화담관염의 유병률은 남성에서 여성보 다 약간 더 높았다. 북미 연구에서는 성별 및 연령 보정 유병 률이 남성과 여성에서 각각 10만 명당 4.9, 3.2였고, 영국에서 는 각각 6.7, 4.4였다.16,17 유병률은 여러 나라에서 증가 추세 를 보이고 있다. 스페인에서 발표된 연구에 따르면, 유병률이 1984년 0.78, 1988년 2.24로 증가하였고,18 영국 자료에 따르 면, 유병률이 1998년 3.23에서 2014년 7.4로 높아졌다.16 일 본에서 발표한 자료도 2007년에서 2016년에 걸쳐 유병률이 0.95에서 1.8로 상향되었다.15 2013년 네덜란드 연구에 따르 면, 원발경화담관염의 유병률은 10만 명당 6.0이었고, 전체 환자의 64%가 남성이었으며, 평균 진단 연령은 39세였다. 전 체 환자 중 68%에서 염증장질환이 있었고, 이중 77%가 궤양 대장염, 19%가 크론병이었다. 92개월 추적기간 동안 7%의 환자에게서 담관암(cholangiocarcinoma)이, 3%에서 대장암 이 발생하였다. 특히, 대장암 발생위험은 원발경화담관염 환 자군이 일반인구군에 비해 5배 더 높았고, 원발경화담관염-궤 양대장염 환자군이 일반인구군에 비해 9배 더 높았다.19 원발 경화담관염의 유병률과 관련된 국내 자료는 아직 없다.

Review the underlying epidemiology source

Epidemiology signal 3: Recent global patterns in skin cancer incidence, mortality, and prevalence

tions to 2040. JAMA Dermatol 2022;158:495–503. doi: 10.1001/ jamadermatol.2022.0160. 14. Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cuta- neous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2014;28:1170–1178. doi: 10.1111/jdv.12236. 15. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemi- ology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119–126. doi: 10.1002/ijc.11360. 16. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015;151:1081– 1086. doi: 10.1001/jamadermatol.2015.1187. 17. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin 2012;30:355–361. doi: 10.1016/j. det.2012.04.001. 18. Cakir BÖ, Adamson P, Cingi C. Epidemiology and economic bur- den of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2012;20:419–422. doi: 10.1016/j.fsc.2012.07.004. 19. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr., Gold- man ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425–429. doi: 10.1067/mjd.2003.186. 20. Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol 2020;156:57–64. doi: 10.1001/jamaderma

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Keratoderma, Palmoplantar, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Keratoderma, Palmoplantar strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor for this landscape is COL1A1. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 35 registered studies overall. Recent sampled records include:

• ChiCTR2600125965 — Benvitimod Cream for the Treatment of Nagashima-type Palmoplantar Keratosis in Adults: A Prospective, Multicenter, Randomized, Double-Blind, Self-Controlled Study; status Not yet recruiting; phase Not Applicable; sponsor Dongguan People's Hospital; enrollment 20.
• ChiCTR2600122580 — Research on the Development and Clinical Validation of Rapid Genetic Diagnostic Technology for Nagashima-type Palmoplantar Keratoderma; status Pending; phase Not Applicable; sponsor Institute of Biomedical Engineering, Chinese Academy of Medical Sciences; enrollment 2000.
• CTRI/2026/04/107754 — Efficacy of local application of Madanadi Lepa in the treatment of Vipadika kushtha in children.; status Not Yet Recruiting; phase Phase 2/3; sponsor Dr. Priyanka Chiripal; enrollment 60.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Keratoderma, Palmoplantar. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Keratoderma, Palmoplantar, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that COL1A1 is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Keratoderma, Palmoplantar merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if COL1A1 modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Keratoderma, Palmoplantar is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.